Synopsis. Abstracts submitted to the EASD 2006 and IDF 2006 conferences. 7 June May Phase 4

Size: px
Start display at page:

Download "Synopsis. Abstracts submitted to the EASD 2006 and IDF 2006 conferences. 7 June May Phase 4"

Transcription

1 Report Body and Synopsis Page: 3 of 81 Synopsis TITLE OF TRIAL A 24-week, multi-centre, controlled, open-labelled, parallel, randomised efficacy and safety comparison of biphasic insulin aspart 30 once daily with metformin vs biphasic insulin aspart 30 monotherapy twice daily in subjects with type 2 diabetes INVESTIGATORS Signatory investigator Dr Hemant A Makan Johannesburg Principal investigators Dr Deepak R Lakha Johannesburg Dr Elizabeth C van den Berg Pretoria Dr Derek Miller Cape Town Dr Essop J Solomon Pietermaritzburg Dr Johann J Viljoen Bloemfontein Dr Frieda D Pienaar Bloemfontein Dr Hans H Snyman Brits Dr Joseph H Mynhardt Kimberley Dr Eric C Kok Cape Town Dr Dudley M Kelbe Richards Bay Dr Hilton Kaplan Cape Town Dr Puvanesveri Naiker Durban Prof Mahomed Abdool Khalek Omar Durban Dr Essack A Mitha Johannesburg Dr Ismail H Mitha Johannesburg TRIAL SITES 80 Gemsbok Avenue, 1827 Johannesburg Starling Street, 1827 Johannesburg. Zuid Afrikaans Hospital, Clinic 2, 0002 Pretoria. 103 Constantiaberg Mediclinic, 7800 Cape Town. Mediclinic Hospital, Payne Street, Block 3 1 st Floor, 3235 Pietermaritzburg. 55 Reid Street, 9301 Bloemfontein. Bloemfontein Mediclinic, Lower Ground Floor Room 1, 9301 Bloemfontein. Armansis Medical Centre, 12 Ludorf Street, 0250 Brits. 153 Du Toitspan Road, 8301 Kimberley. Kenilworth Medical Centre, 67 Rosmead Avenue, 7708 Cape Town. Richards Bay Trial Centre, Suite 6 Calypso Center, Kruger Rand Road, 3900 Richards Bay. 249 Main Road, 7708 Cape Town. 107 Chelmsford Road, St Augustine Hospital, 4001 Durban. 75 Hopelands Road, Centre for Diabetes & Endocrinology, 4091 Durban. Suite DF3, Newgate Centre, 2118 Johannesburg. No 1, Mowbray Avenue, Benoni, 1501 Johannesburg. PUBLICATIONS Abstracts submitted to the EASD 2006 and IDF 2006 conferences. TRIAL PERIOD 7 June May DEVELOPMENT PHASE Phase 4

2 Report Body and Synopsis Page: 4 of 81 OBJECTIVES Primary Objective: To compare the glycaemic control, measured as the level of glycosylated haemoglobin A 1c (HbA 1c ), of biphasic insulin aspart 30 (BIAsp 30) administered once daily plus metformin with that of BIAsp 30 administered twice daily in subjects with type 2 diabetes. Secondary Objectives: To compare the overall glycaemic control, between the two treatments, as measured by fasting plasma glucose (FPG), 8-point plasma glucose (PG) profiles (pre and post meals, bedtime and 2am) performed during the last week prior to Visits 2 and 7 (end of treatment) and 7-point PG profiles (pre and post meals and bedtime) performed during the last week prior to Visits 3 to 6. These comparisons are to include variations in postprandial increments. The incidence of hypoglycaemic episodes (minor, major and symptomatic) recorded during the 20-week maintenance period (nocturnal 23:00-06:00 and diurnal 06:00-23:00). The cardiovascular risk factors as assessed by triglyceride, total cholesterol, LDL- and HDL-cholesterol after 24 weeks of treatment. The safety profile as measured by the incidence of adverse events (AEs) during the treatment period. The safety profile as measured by laboratory safety parameters (haematology and biochemistry and physical examination). Weight and vital signs measured during the treatment period. METHODOLOGY This was a multi-centre, open-labelled, symmetrically randomised (1:1) two-armed parallel group trial of 24 weeks duration comparing BIAsp 30 administered once daily at dinner plus metformin dosed, at the Investigator s discretion, as per local practice, up to 3000mg a day to BIAsp 30 administered twice daily, once in the morning and once at dinnertime, to subjects with type 2 diabetes. NUMBER OF SUBJECTS PLANNED AND ANALYSED 160 subjects were planned to enter this trial. 140 subjects were randomised into treatment groups and exposed to trial product. 5 subjects with no post baseline HbA 1c data were excluded from the intent-to-treat (ITT) population. 135 subjects constituted the ITT population. 14 subjects withdrew from the trial due to AEs (3 subjects), ineffective therapy (3 subjects), non-compliance with therapy (4 subjects) and other reasons (4 subjects). 126 subjects completed the trial. 91 subjects constituted the per protocol (PP) population. DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION Subjects with type 2 diabetes who were being treated with maximum doses of sulphonylurea or metformin monotherapy or oral combination therapy for at least 2 months. Aged 18 years. Body mass index (BMI) 40.0kg/m 2. HbA 1c 7.5% and 13.0%. TEST PRODUCT, DOSE AND MODE OF ADMINISTRATION, BATCH NUMBER BIAsp 30 (Batch no. B NP51475) 100U/mL, administered using pre-filled 3mL FlexPen delivery device. BIAsp 30 was injected subcutaneously once or twice daily at individualised doses. Rolab metformin HCl 500mg or 850mg were administered orally for subjects in the combination therapy group. DURATION OF TREATMENT A total of 24 weeks which included a 4-week titration period and a 20-week maintenance period. REFERENCE THERAPY, DOSE AND MODE OF ADMINISTRATION, BATCH NUMBER None.

3 Report Body and Synopsis Page: 5 of 81 CRITERIA FOR EVALUATION EFFICACY The primary efficacy endpoint was: HbA 1c. The secondary efficacy endpoints were: 7-point and 8-point PG profiles (pre and post meals, bedtime and 2am). Cardiovascular risk factors (triglyceride, total cholesterol, LDL- and HDL-cholesterol). CRITERIA FOR EVALUATION SAFETY Incidence of hypoglycaemic episodes (minor, major and symptomatic nocturnal and diurnal). AEs. Haematology and biochemistry. STATISTICAL METHODS Three trial populations were defined for the statistical analysis, the intent-to-treat (ITT) population, a per-protocol (PP) population and a safety population. The primary efficacy analysis was based on both the ITT and PP analysis sets. All other analyses were based on the ITT analysis sets. Exploratory analysis based on the PP population was also presented for the secondary efficacy endpoints if > 20% of the completed subjects were excluded from the PP population. Statistical test was not performed if > 35% of the completed subjects had missing data in the endpoints. Efficacy was assessed by HbA 1c, FPG, 7-point and 8-point PG profiles (pre and post meals, bedtime and 2am, including prandial PG increments [2 hours postprandial minus preprandial value]) and plasma lipids. HbA 1c at 24 weeks was analysed using ANOVA with adjustment to baseline. Comparison between treatments was performed using a predefined non-inferiority criterion of 0.6%. Safety was evaluated by incidence of hypoglycaemic episodes and AEs. DEMOGRAPHY OF TRIAL POPULATION As summarised in the table below, demography and baseline characteristics of subjects appeared similar in both treatment groups. BIAsp30 + MET BIAsp30 o.d. b.i.d Number of Subjects Exposed Age, years Mean (SD) 52.9 ( 9.4) 53.3 (10.4) Median Min - Max Sex, N (%) Female 30 (45.5%) 30 (43.5%) Male 36 (54.5%) 39 (56.5%) BMI, kg/m^2 Mean (SD) 28.8 ( 5.0) 29.5 ( 4.4) Median Min - Max Duration of Diagnosed Diabetes, years Mean (SD) 9.7 ( 7.0) 8.2 ( 5.9) Median Min - Max Retinopathy, N (%) No 58 (87.9%) 61 (88.4%) Yes 8 (12.1%) 8 (11.6%) Neuropathy, N (%) No 59 (89.4%) 59 (85.5%) Yes 7 (10.6%) 10 (14.5%)

4 Report Body and Synopsis Page: 6 of 81 Nephropathy, N (%) No 64 (97.0%) 65 (94.2%) Yes 2 ( 3.0%) 4 ( 5.8%) Macroangiopathy, N (%) No 57 (86.4%) 64 (92.8%) Yes 9 (13.6%) 5 ( 7.2%) HbA1c at Visit 1, % Mean (SD) 10.1 ( 1.4) 10.2 ( 1.4) Median Min - Max Diabetes Therapy at baseline, N (%) Monotherapy 6 ( 9.1%) 5 ( 7.2%) Oral Combination Therapy 60 (90.9%) 64 (92.8%) Duration of Current Diabetes Therapy, years Mean (SD) 3.1 ( 4.2) 2.1 ( 2.7) Median Min - Max Types of OADs, N (%) VISIT 2 (taken on day of 8-point PG profile) Biguanides and Meglitinides 1 ( 1.5%) 1 ( 1.4%) Biguanides and Sulphonlyureas 57 (86.4%) 63 (91.3%) Biguanides only 4 ( 6.1%) 0 ( 0.0%) Sulphonlyureas and TZD 0 ( 0.0%) 1 ( 1.4%) Sulphonlyureas and alpha-gi 1 ( 1.5%) 0 ( 0.0%) Sulphonlyureas only 2 ( 3.0%) 4 ( 5.8%) EFFICACY RESULTS After 24 weeks of treatment, glycaemic control was improved in both treatment groups: HbA 1c was reduced by 1.90 ± 1.44% in the once daily BIAsp 30 with metformin group and 1.62 ± 1.74% in the twice daily BIAsp 30 monotherapy group. Non-inferiority of once daily BIAsp 30 with metformin to twice daily BIAsp 30 monotherapy was shown (difference %; 95% CI [-0.752; 0.129]). Mean FPG decreased from baseline in the once daily BIAsp 30 with metformin group (-2.99 ± 3.13mmol/L) and in the twice daily BIAsp 30 monotherapy group (-2.16 ± 3.93mmol/L). The statistically significant treatment difference in FPG was mmol/L (95% CI ; ; p=0.010). At the final visit (LOCF), a lower prandial increment in PG at breakfast was observed in the twice daily BIAsp 30 monotherapy group (0.234mmol/L) than in the once daily BIAsp 30 with metformin group (2.275mmol/L). The change in breakfast prandial PG increment from baseline (Visit 2) to the final visit (LOCF) was -0.39mmol/L in the once daily BIAsp 30 with metformin group and -2.25mmol/L in the twice daily BIAsp 30 monotherapy group. After adjusting for baseline, there was a statistically significant treatment difference of ± 0.51mmol/L, 95% CI=1.025;3.057, p<0.001 at the final visit. However, a lower prandial increment in PG at lunch at the final visit (LOCF) was observed in the once daily BIAsp 30 with metformin group (1.324mmol/L) than in the twice daily BIAsp 30 monotherapy group (2.922mmol/L). The change in lunch prandial PG increment from baseline (Visit 2) to the final visit (LOCF) was -0.35mmol/L in the once daily BIAsp 30 with metformin group and 1.30mmol/L in the twice daily BIAsp 30 monotherapy group. After adjusting for baseline, there was a statistically significant treatment difference of ± 0.56mmol/L, 95% CI= ;-0.479, p=0.006 at the final visit. Similar to the result at lunch, a lower prandial increment in PG at dinner at the final visit (LOCF) was observed in the once daily BIAsp 30 with metformin group (-0.109mmol/L) than in the twice daily BIAsp 30 monotherapy group (0.907mmol/L). The change in dinner prandial PG increment from baseline (Visit 2) to the final visit (LOCF) was -2.76mmol/L in the once daily BIAsp 30 with metformin group and -1.29mmol/L in the twice daily BIAsp 30 monotherapy group. After adjusting for baseline, there was a statistically significant treatment difference of ± 0.50mmol/L, 95% CI=-2.012;-0.019, p=0.046 at the final visit. At the final visit (LOCF), a lower PG at bedtime was observed in the once daily BIAsp 30 with metformin group (7.249mmol/L) than in the twice daily BIAsp 30 monotherapy group (7.574mmol/L). The change in bedtime

5 Report Body and Synopsis Page: 7 of 81 prandial PG value from baseline (Visit 2) to the final visit (LOCF) was -4.17mmol/L in the once daily BIAsp 30 with metformin group and -4.04mmol/L in the twice daily BIAsp 30 monotherapy group. After adjusting for baseline, the non-statistically significant treatment difference was ± 0.67mmol/L, 95% CI=-1.645;0.995, p=0.626 at the final visit. At the final visit (LOCF), a lower PG at 2am was observed in the once daily BIAsp 30 with metformin group (6.964mmol/L) than in the twice daily BIAsp 30 monotherapy group (7.399mmol/L). The change in 2am PG value from baseline (Visit 2) to the final visit (LOCF) was -3.39mmol/L in the once daily BIAsp 30 with metformin group and -2.88mmol/L in the twice daily BIAsp 30 monotherapy group. After adjusting for baseline, the nonstatistically significant treatment difference was ± 0.58mmol/L, 95% CI=-1.589;0.720, p=0.457 at the final visit. Total cholesterol decreased by 0.12 ± 1.02mmol/L in the once daily BIAsp 30 with metformin group and increased by 0.21 ± 0.88mmol/L in the twice daily BIAsp 30 monotherapy group (statistically significant treatment difference -0.34mmol/L; 95% CI [-0.678; ]). Other parameters (LDL-, HDL-cholesterol and triglycerides) were comparable in the change from baseline (Visit 2) to the final visit (LOCF) in both treatment groups. SAFETY RESULTS After 24 weeks of treatment with either once daily BIAsp 30 with metformin or twice daily BIAsp 30 monotherapy: The AE profile was comparable between treatment groups, with a total of 275 events reported by 108 subjects: 73% reported 124 TEAEs in the once daily BIAsp 30 with metformin group and 81% reported 151 TEAEs in the twice daily BIAsp 30 monotherapy group. The majority of subjects reported AEs in both treatment groups were mild (61% in the once daily BIAsp 30 with metformin group and 60% in the twice daily BIAsp 30 monotherapy group) or moderate (33% in the once daily BIAsp 30 with metformin group and 50% in the twice daily BIAsp 30 monotherapy group). These AEs were unlikely to be related to trial product (71% in the once daily BIAsp 30 with metformin group reported 114 events and 79% in the twice daily BIAsp 30 monotherapy group reported 145 events), as judged by the Investigator and Sponsor. A total of 3 subjects from the twice daily BIAsp 30 monotherapy group were withdrawn due to AEs. The events leading to withdrawal were: fibromyalgia (severe and probable relation), insulin resistance (mild severity and probable relation) and weight gain (moderate severity and probable relation). A total of 262 non-saes were reported by 107 subjects: 73% reported 122 events in the once daily BIAsp 30 with metformin group and 80% reported 140 events in the twice daily BIAsp 30 monotherapy group. There were 13 SAEs reported by 9 subjects: 2 SAEs reported by 1 subject in the once daily BIAsp 30 with metformin group and 11 SAEs reported by 8 subjects in the twice daily BIAsp 30 monotherapy group. Except for 1 subject (Screening ID 0518) who had recovered with sequelae, all the subjects with treatment emergent SAEs had recovered from the event. All the events were judged by the Investigator and Sponsor as unlikely to be related to trial product. A total of 94 hypoglycaemic episodes were reported by 28 subjects (40%) on once daily BIAsp 30 with metformin and 147 hypoglycaemic episodes by 30 subjects (43%) on twice daily BIAsp 30 monotherapy, of which the majority were minor (29% and 27%) or symptomatic (23% and 31%). A major episode of hypoglycaemia was reported in the once daily BIAsp 30 with metformin group. In both treatment groups, minor/symptoms only hypoglycaemic episodes mostly (71 out of 88 events and 129 out of 144 events) occurred during the day. The change in body weight was 0.50 ± 3.33kg in the once daily BIAsp 30 with metformin group and 3.69 ± 4.91kg in the twice daily BIAsp 30 monotherapy group. Vital signs or the results of physical examinations remained generally unchanged in both treatment groups. ECG and fundoscopy results were normal in 79% and 83% of the subjects, respectively in both treatment groups. CONCLUSIONS After 24 weeks of treatment with either once daily BIAsp 30 with metformin or twice daily BIAsp 30 monotherapy in type 2 diabetes subjects: Comparable improvements in glycaemic control as observed in HbA 1c and PG were achieved in both treatment groups with non-inferiority of once daily BIAsp 30 with metformin to twice daily BIAsp 30 monotherapy

6 Report Body and Synopsis Page: 8 of 81 confirmed. An improvement in total cholesterol was observed in the once daily BIAsp 30 with metformin group. Other parameters in the lipids profile were comparable between treatment groups. The occurrence of hypoglycaemic episodes of which the majority were minor or symptomatic was comparable between treatment groups. Similarly, the incidences of AEs of which the majority were mild in severity and considered unlikely to be related to trial product were comparable between treatment groups. The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.

Synopsis. None. The trial was started on 13 January 2003 and completed on 02 November Phase 4. Primary Objective:

Synopsis. None. The trial was started on 13 January 2003 and completed on 02 November Phase 4. Primary Objective: Report Body and Synopsis Page: 3 of 53 Synopsis TITLE OF TRIAL A Multinational, Randomised, Controlled, Open-labeled, Parallel Group Evaluation in Terms of Efficacy and Safety of Metformin 1700 mg/day

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

premix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence

premix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Study Code: Date: 27 July 2007

Study Code: Date: 27 July 2007 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Efficacy/pharmacodynamics: 85 Safety: 89

Efficacy/pharmacodynamics: 85 Safety: 89 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:

More information

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779) TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)

23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin

More information

Number of patients: Planned: 403 Randomized: 391 Treated: 390 Efficacy: 363 (Full analysis set) 356 (Per-protocol set)

Number of patients: Planned: 403 Randomized: 391 Treated: 390 Efficacy: 363 (Full analysis set) 356 (Per-protocol set) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company : sanofi-aventis

More information

ClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites

ClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:

More information

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes

The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes This trial is conducted in Europe and North America. The

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,

More information

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company: These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

Sponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490

Sponsor / Company: Sanofi Drug substance(s): AMARYL M (1/250 mg) / HOE490 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Individualising Insulin Regimens: Premixed or basal plus/bolus?

Individualising Insulin Regimens: Premixed or basal plus/bolus? Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin

More information

SYNOPSIS. Administration: subcutaneous injection Batch number(s):

SYNOPSIS. Administration: subcutaneous injection Batch number(s): SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2

More information

Early treatment for patients with Type 2 Diabetes

Early treatment for patients with Type 2 Diabetes Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION London, 5 October 2005 Product name: NovoMix Procedure No. EMEA/H/C/308/X/18 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis

Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis Christine Clar*, Pamela Royle, Norman Waugh Department of Public Health, University of Aberdeen,

More information

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand

More information

Pramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon

Pramlintide & Weight. Diane M Karl MD. The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Pramlintide & Weight Diane M Karl MD The Endocrine Clinic & Oregon Health & Science University Portland, Oregon Conflict of Interest Speakers Bureau: Amylin Pharmaceuticals Consultant: sanofi-aventis Grant

More information

Sponsor: Sanofi. According to template: QSD VERSION N 5.0 (04-APR-2016) Page 1

Sponsor: Sanofi. According to template: QSD VERSION N 5.0 (04-APR-2016) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Timely!Insulinization In!Type!2! Diabetes,!When!and!How Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for

More information

A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide

A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D. Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

MANAGEMENT OF DIABETES IN PREGNANCY

MANAGEMENT OF DIABETES IN PREGNANCY MANAGEMENT OF DIABETES IN PREGNANCY Ministry of Health Malaysia Malaysian Endocrine & Metabolic Society Perinatal Society of Malaysia Family Medicine Specialists Association of Malaysia Academy of Medicine

More information

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010 Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

To assess the safety and tolerability in each treatment group.

To assess the safety and tolerability in each treatment group. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

Individual Study Table Referring to Part of the Dossier. Volume: Page:

Individual Study Table Referring to Part of the Dossier. Volume: Page: 2 CLINICAL STUDY SYNOPSIS FINAL REPORT N0. CCD-0402-RS-0002 Title of the study: Evaluation of the 24-hour trough FEV 1 following 7 days of dosing with 2 µg once daily. A multicentre, double-blind, double-dummy,

More information

Study No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of

Study No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Study No.: 49653/020 Title: A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered

More information

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Insulin Initiation, titration & Insulin switch in the Primary Care-KISS Rotorua GP CME 9 June 2012 Dr Kingsley Nirmalaraj FRACP Endocrinologist, BOPDHB & Suite 9, Promed House, Tenth Ave, Tauranga Linda

More information

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight

More information

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309

More information

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK

More information

Starting Insulin in General Practice

Starting Insulin in General Practice Starting Insulin in General Practice Timothy Kenealy GP & Assoc Prof of Integrated Care, University of Auckland Auckland DHB / my version + Counties DHB version Starting Insulin surprisingly simple, safe

More information

Francesca Porcellati

Francesca Porcellati XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia

More information

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

Insulin Intensification: A Patient-Centered Approach

Insulin Intensification: A Patient-Centered Approach MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director

More information

Glucose Control drug treatments

Glucose Control drug treatments Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients

More information

Re-Submission: Published 10 March February 2014

Re-Submission: Published 10 March February 2014 Re-Submission: insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 07 February

More information

exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited

exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female

More information

insulin degludec (Tresiba ) is not recommended for use within NHS Scotland.

insulin degludec (Tresiba ) is not recommended for use within NHS Scotland. insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish

More information

04-Sep-17. INERTIA a failure to initiate or modify treatment in a timely manner in people whose health is likely to improve with this modification

04-Sep-17. INERTIA a failure to initiate or modify treatment in a timely manner in people whose health is likely to improve with this modification PROF MERLIN THOMAS DIAttitude Study INERTIA a failure to initiate or modify treatment in a timely manner in people whose health is likely to improve with this modification 13% immediately 41% of patients

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Novomix. This scientific discussion has been updated until 1 September 2004. For information on changes

More information

Mipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3

Mipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3 (ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,

More information

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136 Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Reyataz Name of Active Ingredient: Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for

More information

PDF of Trial CTRI Website URL -

PDF of Trial CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Tue, 16 Apr 2019 03:04:45 GMT) CTRI Number Last Modified On 29/11/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Clinical Trial Synopsis TL-OPI-525, NCT#

Clinical Trial Synopsis TL-OPI-525, NCT# Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS

More information

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER 2. SYNOPSIS Title of Study: An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of and a Single Dose of Rosuvastatin (Crestor ), to Assess the Dose Proportionality of,

More information

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive

More information

Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar )

Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar ) Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar ) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Toujeo uses the same

More information

2. SYNOPSIS Name of Sponsor/Company:

2. SYNOPSIS Name of Sponsor/Company: in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

New Medicine Assessment

New Medicine Assessment New Medicine Assessment Insulin Glargine 300 units/ml (Toujeo ) Treatment of type 2 diabetes mellitus in adults Recommendation: Amber 0 Insulin glargine 300 units/ml (Toujeo ) is recommended as an option

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before

More information

Sponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225

Sponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 30 May 2002 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL

More information

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T Supplementary Data Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles 1 T Z T O jig(t) IGjdt IG, interstitial glucose; IG(t), IG value at time t; IG, mean IG from the

More information

insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S

insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed

More information

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with

More information

TUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS

TUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS DIABETES MELLITUS 1. Introduction Diabetes is a global epidemic with 415 million people affected worldwide equivalent to the total population of the USA, Canada and Mexico. In recognition of this, the

More information

Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus

Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus 1 2 3 29 January 2018 CPMP/EWP/1080/00 Rev. 2 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on clinical investigation of medicinal products in the treatment or prevention Draft

More information

The hallmark of type 2 diabetes mellitus (T2DM) is progressive

The hallmark of type 2 diabetes mellitus (T2DM) is progressive 16 SUPPLEMENT TO JAPI january 2013 VOL. 61 Original Article Initiating Therapy or Switching to Biphasic Insulin Aspart Improves Glycaemic Control in Type 2 Diabetes: An Indian Experience from the A 1 chieve

More information

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study

Statistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study 1.0 Page 1 of 15 FINAL DexComG4 (DexCom Corporation) CGMMDI GOLD-Study monitoring (CGM) in individuals with type 1 diabetes treated 2016-07-07 Approvals Name/Title: Nils-Gunnar Pehrsson / Statistiska Konsultgruppen,

More information

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page: SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged

More information

Challenges in type 2 diabetes control: slipping control and weight gain

Challenges in type 2 diabetes control: slipping control and weight gain control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists

More information

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301 SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in

More information

January 7, 5:00 p.m. EST

January 7, 5:00 p.m. EST Study 3-151 Phase 2 Trial: Preliminary Results BIOD-531, a Concentrated Ultra-Rapid-Acting Prandial/Basal Insulin, Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins

More information

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia

More information

ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ

ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process

More information

Clinical Trial Synopsis TL-OPI-518, NCT#

Clinical Trial Synopsis TL-OPI-518, NCT# Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride

More information

New Medicine Assessment

New Medicine Assessment New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2

More information

dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.

dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its

More information

S. W. Park 1, W. M. W. Bebakar 2, P. G. Hernandez 3, S. Macura 4, M. L. Hersløv 5 and R. de la Rosa 6. Abstract. Introduction

S. W. Park 1, W. M. W. Bebakar 2, P. G. Hernandez 3, S. Macura 4, M. L. Hersløv 5 and R. de la Rosa 6. Abstract. Introduction DIABETICMedicine Research: Treatment Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST â : SIMPLE USE) S. W. Park 1, W. M. W.

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia

Sponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP

Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical

More information

ADA Analyst Presentation Saturday 9 th June

ADA Analyst Presentation Saturday 9 th June ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme

More information

Application of the Diabetes Algorithm to a Patient

Application of the Diabetes Algorithm to a Patient Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

DMEP Study Section 1 1

DMEP Study Section 1 1 DMEP Study Section 1 1 1. EXECUTIVE SUMMARY 1.1 Objectives The specific aims of the Diabetes Mellitus Education Program (DMEP) were to examine the role of the community pharmacist in the disease state

More information